Bio: Nynke Kramer is associate professor in toxicology at the Toxicology Division of the Agrotechnology and Food Sciences group of Wageningen University. She teaches toxicology, toxicokinetics and (eco) toxicological risk assessment at undergraduate, graduate, and postgraduate level. Before starting at Wageningen University in September 2021, she was assistant professor in toxicology at the Institute for Risk Assessment Sciences (IRAS) of Utrecht University, where she also obtained her PhD in 2010. Her research focuses on enhancing the uptake of in vitro models in chemical safety assessment by developing models extrapolating toxic concentrations in in
peer-reviewed publications identifying physiological and chemical parameters underlying the accumulation of toxicants in cells in the body and in in in vitro toxicity assays. Illustratively, Nynke’s research has been awarded the SETAC Procter and Gamble Fellowship for Doctoral Research in Environmental Sciences. She used the prize money to do part of her research at the Swiss Federal Institute for Aquatic Science and Technology, Eawag, Dübendorf, Switzerland. Before starting her PhD, Nynke obtained her BSc degree in Life Sciences at University College Utrecht and her MSc degree in Environmental Change and Management at the University of Oxford.
Abstract: Emerging mycotoxins, such as enniatins (ENNs) A, A1, B, and B1, are increasingly detected in food and feed, raising concerns about their potential health risks. However, limited toxicokinetic and toxicity data and the absence of established regulatory thresholds hinder comprehensive risk assessment. Physiologically Based Kinetic (PBK) modelling offers a powerful tool to bridge this data gap by integrating data from New Approach Methodologies (NAMs) to relate external and target tissue exposures. When applying PBK modelling in a reverse dosimetry fashion, effect concentrations from in vitro toxicity assays may be translated to human bioequivalent oral doses in an approach referred to as quantitative in vitro-in vivo extrapolation (QIVIVE), which can then be used as points of departure for risk assessment. This study presents the development of a read-across PBPK model for mycotoxins for use in a NAMs based risk assessment. Key toxicokinetic and toxicity parameters were derived from human-relevant in vitro models, including the rapid equilibrium dialysis (RED) assay, Caco-2 permeability studies, and in vitro intrinsic clearance studies with intestinal and liver S9. Model validation was performed using available data from animal studies and applied to predict the kinetics and toxicity of mycotoxins for which animal data is missing.
10
0
0
Date | Time | Local Time | Room | Forum | Session | Role | Topic |
---|---|---|---|---|---|---|---|
2025-10-16 | 17:30-18:00 | 2025-10-16,17:30-18:00 | Room 4 - Guohua Hall | Symposium Program (Session) |
Session 10: PARC – New Approaches to Model Kinetic Properties |
Speaker | PBK model-based QIVIVE for a NAMs based assessment of emerging mycotoxins |